Literature DB >> 16627025

Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.

Lilian I Plotkin1, Stavros C Manolagas, Teresita Bellido.   

Abstract

Bisphosphonates induce osteoclast apoptosis, thereby decreasing bone resorption and reducing the rate of bone remodeling. Earlier work from our group and others has demonstrated that, additionally, bisphosphonates prevent osteoblast and osteocyte apoptosis in vivo and in vitro, raising the possibility that perhaps part of their anti-fracture efficacy may result from preserving the integrity of the osteocyte network and prolonging the working time of bone forming cells. Whereas induction of osteoclast apoptosis results from inhibition of the mevalonate pathway or from conversion to toxic ATP analogs, prevention of osteoblastic cell apoptosis is mediated by connexin43 hemichannel opening and activation of the extracellular signal-regulated kinases (ERKs). We examined here the ability of several bisphosphonates, including novel analogs, to exert these two effects. All 16 bisphosphonates studied inhibited etoposide-induced apoptosis of MLO-Y4 osteocytic cells and osteoblastic cells derived from calvaria, with EC50 between 10(-12) and 10(-10) M. On the other hand, only 10 analogs induced apoptosis of RAW-264.7-cell-derived osteoclasts. Each of the 6 bisphosphonates that lack pro-apoptotic activity in osteoclasts but retain anti-apoptotic activity in osteoblasts and osteocytes has a structural-related analog that is active in both cell types. These findings indicate that the structural prerequisites for the anti-apoptotic effect of bisphosphonates on cells of the osteoblastic lineage are less stringent than the ones required to induce osteoclast apoptosis and confirm that bisphosphonates act on the two cell types by distinct mechanisms. Preservation of osteoblast and osteocyte viability without inducing osteoclast apoptosis by these bisphosphonates analogs opens new possibilities for the treatment of bone fragility in conditions in which a decrease in bone remodeling is not desirable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627025     DOI: 10.1016/j.bone.2006.02.060

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  46 in total

Review 1.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

Review 2.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

Review 3.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

4.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

5.  Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.

Authors:  Lilian I Plotkin; Virginia Lezcano; Jeff Thostenson; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

6.  Osteoconductive action of alendronate after implantation of beta tricalcium phosphate in rat adjuvant-induced arthritis.

Authors:  Takahiro Netsu; Naoki Kondo; Katsumitsu Arai; Akira Ogose; Naoto Endo
Journal:  J Bone Miner Metab       Date:  2012-07-18       Impact factor: 2.626

7.  Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.

Authors:  K Ebina; T Noguchi; M Hirao; J Hashimoto; S Kaneshiro; M Yukioka; H Yoshikawa
Journal:  Osteoporos Int       Date:  2016-01       Impact factor: 4.507

8.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

9.  Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells.

Authors:  Jun Chang; Wei Wang; Hui Zhang; Yong Hu; Zongsheng Yin
Journal:  Oncol Lett       Date:  2012-05-21       Impact factor: 2.967

Review 10.  Beyond gap junctions: Connexin43 and bone cell signaling.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Bone       Date:  2012-10-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.